RTP Mobile Logo

Saturday, June 2, 2018, Chicago, IL, 6:45 AM – 7:45 AM

Breakfast with the Investigators: Management of Melanoma

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:15 AM – 6:45 AM (Central Time) — Registration
6:45 AM – 7:45 AM (Central Time) — Educational Breakfast Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Michael A Postow, MD
Medical Oncologist
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, New York

Prof Caroline Robert, MD, PhD
Chief, Dermato-Oncology
Co-Director, Melanoma Team INSERM
Gustave-Roussy Institute
Paris, France

Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Merck and Novartis.


Meeting Format and Agenda

This unique activity will feature several distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Current and Future Role of Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma

  • Clinical, biologic and practical factors influencing the use of anti-PD-1 monotherapy versus immune checkpoint inhibitor combination therapy
  • Role of PD-L1 expression as a predictive marker of response to immune checkpoint inhibitors
  • Other potential predictors of response to immune checkpoint inhibition (eg, tumor mutational burden, composition of gut microbiome)
  • Efficacy and safety of immune checkpoint inhibition in patients with brain metastases
  • Incidence and management of autoimmune toxicities associated with immune checkpoint inhibitors; considerations for patients with preexisting autoimmune conditions
  • Investigational approaches combining immune checkpoint inhibitors with targeted therapy or other immunotherapies

MODULE 2: Integration of BRAF/MEK Inhibitors into the Management of BRAF-Mutated Disease

  • Molecular and biologic similarities and differences among the approved and investigational BRAF/MEK inhibitor combinations
  • Comparative efficacy and safety of the approved BRAF/MEK inhibitor combinations dabrafenib/trametinib and vemurafenib/cobimetinib
  • Design, eligibility criteria and key efficacy and safety outcomes from the Phase III COLUMBUS trial evaluating encorafenib with binimetinib versus vemurafenib or encorafenib for BRAF-mutated melanoma
  • Potential role of encorafenib/binimetinib in clinical practice
  • Incidence, prevention and management of side effects and toxicities associated with available BRAF and MEK inhibitor combinations
  • Emerging data with and ongoing investigation of checkpoint inhibitors added to BRAF/MEK inhibitor combinations for metastatic melanoma

MODULE 3: Evolving Treatment Approaches for Patients with Localized or Locally Advanced Disease

  • COMBI-AD: Results from a Phase III trial of adjuvant dabrafenib and trametinib for resected Stage III BRAF-mutated melanoma
  • Design, entry criteria and primary and secondary efficacy outcomes of the Phase III CheckMate 238 trial evaluating adjuvant ipilimumab versus nivolumab
  • Clinical implications of the recent FDA approvals of nivolumab and the combination dabrafenib/trametinib as adjuvant therapy; potential factors influencing selection of treatment approach
  • Management of side effects associated with the adjuvant use of immune checkpoint inhibitors and BRAF/MEK inhibitor combinations
  • Novel treatment strategies under investigation for localized and locally advanced melanoma

CE Information

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and potential benefits of existing and recently approved systemic approaches.
  • Consider age, performance status and other disease-related factors to guide the selection of first and later-line therapy for patients with metastatic BRAF wild-type melanoma.
  • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic BRAF mutation-positive advanced melanoma.
  • Recall current investigational efforts to identify biomarkers of response to immune checkpoint inhibition, and consider how these may be applied in future clinical practice.
  • Recognize adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize and/or manage side effects.
  • Recall new data with investigational agents and strategies demonstrating promising activity in melanoma, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Merck and Novartis.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:15 AM (Central Time) on Saturday, June 2nd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.